Design, Characterization, and Biopharmaceutical Behavior of Nanoparticles Loaded with an HIV-1 Fusion Inhibitor Peptide

Molecular Pharmaceutics
Martha Ariza-SáenzMaría Luisa García

Abstract

New therapeutic alternatives to fight against the spread of HIV-1 are based on peptides designed to inhibit the early steps of HIV-1 fusion in target cells. However, drawbacks, such as bioavailability, short half-life, rapid clearance, and poor ability to cross the physiological barriers, make such peptides unattractive for the pharmaceutical industry. Here we developed, optimized, and characterized polymeric nanoparticles (NPs) coated with glycol chitosan to incorporate and release an HIV-1 fusion inhibitor peptide (E1) inside the vaginal mucosa. The NPs were prepared by a modified double emulsion method, and optimization was carried out by a factorial design. In vitro, ex vivo, and in vivo studies were carried out to evaluate the optimized formulation. The results indicate that the physicochemical features of these NPs enable them to incorporate and release HIV fusion inhibitor peptides to the vaginal mucosa before the fusion step takes place.

References

Jun 11, 1999·Contraception·D H Owen, D F Katz
Mar 17, 2001·Advanced Drug Delivery Reviews·H TakeuchiY Kawashima
Sep 8, 2001·The New England Journal of Medicine·J XiangJ T Stapleton
Jul 11, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Cory BerklandDaniel W Pack
Aug 23, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Fan Tao MengZhi Guo Su
Aug 7, 2004·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·S M van der MerweH E Junginger
Sep 1, 2005·Luminescence : the Journal of Biological and Chemical Luminescence·Cristina LariosM Asunción Alsina
Sep 20, 2005·Advanced Drug Delivery Reviews·Hirofumi TakeuchiYoshiaki Kawashima
Nov 17, 2006·The Journal of Physical Chemistry. B·C LariosJ Miñones Trillo
Feb 10, 2007·International Journal of Pharmaceutics·N S BerchaneM J Andrews
May 29, 2007·Journal of Molecular Biology·Mónica Fernández-VidalStephen H White
Aug 10, 2007·Acta Biochimica Et Biophysica Sinica·Jilie Kong, Shaoning Yu
Aug 28, 2007·Journal of Pharmaceutical Sciences·Christopher A SquierCatherine C Davis
Jan 26, 2008·Nano Letters·Pascale R LeroueilMark M Banaszak Holl
Feb 6, 2008·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Maria Cristina BonferoniCarla Caramella
Nov 13, 2008·Pharmaceutical Research·Anthony S HamLisa Cencia Rohan
Feb 6, 2009·The AAPS Journal·Lisa Cencia Rohan, Alexandra B Sassi
Feb 6, 2009·The Journal of Physical Chemistry. B·Silvia Pérez-LópezConcepció Mestres
Apr 1, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hae Yun NamSeo Young Jeong
Jun 2, 2009·International Journal of Pharmaceutics·Adriana TrapaniThomas Kissel
Sep 30, 2009·Analytica Chimica Acta·Riccardo Leardi
Nov 3, 2009·Drug Discovery Today·Patrick VliegheMichel Khrestchatisky
Jul 20, 2010·International Journal of Pharmaceutics·Shaoling Zhang, Kohsaku Kawakami
Sep 15, 2010·Expert Opinion on Drug Delivery·Nicolas Duceppe, Maryam Tabrizian
Oct 6, 2010·Molecular Pharmaceutics·Shayna L McGill, Hugh D C Smyth
Feb 11, 2011·Current Infectious Disease Reports·Esaki Muthu ShankarSuniti Solomon
May 14, 2011·Journal of Colloid and Interface Science·Maria Jesús Sánchez-MartínM Antònia Busquets
Jun 7, 2011·International Journal of Pharmaceutics·Susanne FredenbergAnders Axelsson
Jun 24, 2011·The Analyst·Andrew W Jones, Helen J Cooper
Jun 28, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Jianing MengBi-Botti C Youan
Oct 28, 2011·The Physician and Sportsmedicine·Karrie Marren
Oct 1, 2010·Journal of Advanced Pharmaceutical Technology & Research·Bindu M BoddupalliDavid Banji
May 12, 2012·Polymers·Hirenkumar K Makadia, Steven J Siegel
Jun 19, 2012·Expert Review of Anti-infective Therapy·Carolynne Schwarze-ZanderJuergen K Rockstroh
Sep 15, 2012·Methods in Molecular Biology·Yuko Ibuki, Tatsushi Toyooka
Sep 26, 2012·Molecular Pharmaceutics·José das NevesBruno Sarmento
Nov 17, 2012·Nature Reviews. Microbiology·Theodora Hatziioannou, David T Evans
Dec 4, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·A L SilvaW Jiskoot

❮ Previous
Next ❯

Citations

Jun 4, 2020·Pharmaceutics·Elena Sánchez-LópezMaría José Gómara
Feb 4, 2021·Nanomaterials·Giulia ChindamoMarina Gallarate
Jul 14, 2021·Bioconjugate Chemistry·Maria J GómaraIsabel Haro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V
Martha Ariza-SáenzMaría Luisa García
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
G Brattebø
© 2022 Meta ULC. All rights reserved